Systematic Review ARTICLE
Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review
- 1Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
- 2Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
- 3Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital-University Health Network and University of Toronto, Toronto, ON, Canada
- 4Division of Epidemiology, Dalla Lana School of Public Health, Toronto, ON, Canada
- 5Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- 6BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada
- 7Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, BC, Canada
- 8Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands
- 9Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands
Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%. Pharmacogenomics has been shown to identify strongly predictive genetic markers to help determine which patients are more likely to experience, for example, a serious adverse drug reaction or receive optimal benefit through enhanced efficacy. Genetic variations have been reported to influence the risk of cisplatin nephrotoxicity; however, a comprehensive overview is lacking.
Methods: A systematic review was performed using Pubmed, Embase and Web of Science on clinical studies that used cisplatin-based chemotherapy as treatment, had available genotyping data, and evaluated nephrotoxicity as an outcome. The quality of reporting was assessed using the STrengthening the REporting of Genetic Association Studies (STREGA) checklist.
Results: Twenty-eight eligible studies were included; all were candidate gene studies. Over 300 SNPs across 135 genes were studied; 29 SNPs in 14 genes were significantly associated with cisplatin-induced nephrotoxicity. A variation in SLC22A2 rs316019, a gene involved in platinum uptake by the kidney, was associated with different measures of nephrotoxicity in four independent studies. Further, variants of ERCC1 (rs11615 and rs3212986) and ERCC2 (rs13181), two genes involved in DNA repair, were found to be positively associated with increased risks of nephrotoxicity in two independent studies.
Conclusion: Three genes consistently associated with cisplatin-induced nephrotoxicity. Further research is needed to assess the biological mechanism and the clinical value of modifying treatment based on SLCC22A2 and ERCC1/2 genotypes.
Platinum-based chemotherapeutics, such as cisplatin, carboplatin, and oxaliplatin are among the most widely used antineoplastics for the treatment of solid tumors. Specifically, cisplatin is part of the first-line regimens used to treat head and neck, lung, testis, ovarian, and bladder cancers (Hanigan and Devarajan, 2003; Pabla and Dong, 2008; McWhinney et al., 2009; Wen et al., 2015). Cisplatin [molecular formula: Cl2H6N2Pt; also known as cisplatinum or cis-diamminedichloroplatinum(II)] is a first generation platinum anticancer agent with a square planar geometry metal ion core (Dasari and Tchounwou, 2014). Cisplatin induces cancer cell death by binding to the N7 reactive center of purine residues and causes irreversible DNA damage in cancer cells during division (Dasari and Tchounwou, 2014), thus blocking cell division and promoting apoptosis. Despite its benefit in cancer therapy, cisplatin is also known for its adverse reactions, such as ototoxicity, neurotoxicity, emesis and nephrotoxicity (Percie du Sert et al., 2011; Wensing and Ciarimboli, 2013; Dasari and Tchounwou, 2014).
Cisplatin-induced nephrotoxicity manifests as acute tubular necrosis (Arany and Safirstein, 2003; Hanigan and Devarajan, 2003; Pabla and Dong, 2008; Miller et al., 2010; Stathopoulos, 2013; Derungs, 2015). Since 27–50% of cisplatin is excreted within 48 hours through the kidneys (Gullo et al., 1980), a high concentration of cisplatin and alteration in renal transport mechanisms (Peres and da Cunha, 2013) has been proposed to lead directly to renal inflammation, oxidative damage, apoptosis, and finally to nephrotoxicity (Yao et al., 2007). The efficacy of cisplatin is dose dependent, but the high risk of nephrotoxicity frequently hinders the use of higher doses to maximize its antineoplastic effects (Schellens et al., 2001; Hanigan and Devarajan, 2003). Previous research has demonstrated that high-dose cisplatin can cause severe renal dysfunction in 20% patients (Yao et al., 2007; Peres and da Cunha, 2013), but the incidence may reach as high as 66% in elderly (Peres and da Cunha, 2013) and over 70% in children (Jimenez-Triana et al., 2015). Long-term platinum retention can be found in the plasma of cancer patients even 20 years after discontinuation of cisplatin-based chemotherapy (Gietema et al., 2000; Hjelle et al., 2015), raising concerns about the long-term nephrotoxicity risks over time.
There is a growing interest in the role of genetic variation in the development of cisplatin nephrotoxicity (Liu et al., 2014; Skinner, 2017). Variations in organic transporter molecules genes (Yonezawa and Inui, 2011; Zhang and Zhou, 2012), DNA repair enzyme genes (Khrunin et al., 2010b; Zhang et al., 2012; Xu et al., 2013), tumor suppressor genes (Liu et al., 2014) and metabolic enzymes involved in platinum detoxification (Barahmani et al., 2009; Khrunin et al., 2012) have been associated with the risk of nephrotoxicity. Although several genetic variants have been identified to influence cisplatin-induced nephrotoxicity in oncology patients, a comprehensive overview on which genetic variations are consistently associated with nephrotoxicity-induced cisplatin-based chemotherapy is lacking.
We conducted a systematic review to identify which genetic variants consistently associated with cisplatin-induced nephrotoxicity in oncology patients and assessed whether there are genetic variants that might be clinically relevant to guide cisplatin treatment.
We carried out a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) (Moher et al., 2009). The protocol was registered in the international prospective register of systematic reviews (PROSPERO; CRD42017064011; Zazuli and Maitland-van der Zee, 2017).
Data Sources and Search Strategy
Our search strategy included articles indexed in PubMed/MEDLINE, EMBASE and Web of Science. See Supplementary Table 1 for Medical Subject Headings (MeSH) terms and keywords used in this study. Additional research papers were identified by screening the reference sections of included articles.
We constructed a PICOS (population-intervention/exposure-comparison-outcome-study design) framework to set out our review objectives (see Supplementary Table 2). All studies needed to fulfil the following inclusion criteria: (1) genetic association studies, (2) studies using cisplatin-containing chemotherapy, (3) studies that included nephrotoxicity as an adverse outcome (any definition), (4) studies published in the English language, and (5) studies involving cancer patients. Preclinical studies (animal experiment or in vitro studies) and studies in which patients were treated with both chemotherapy and radiation therapy were excluded.
After identifying the articles, primary screening by ZZ was performed to determine whether the study met the inclusion criteria based on the abstract. The full paper was evaluated to determine whether an analysis of the association between genetic polymorphisms and platinum induced nephrotoxicity had been performed.
Data Collection and Quality Assessment
The following data were extracted from each publication: source of study (reference), study design (retrospective, case-control, prospective), setting (type of chemotherapy treatment, type and stage of cancer), patient selection (sample size, inclusion and exclusion criteria), observation period (number of treatment cycles) and nephrotoxicity data (definition, scoring system, level of severity) and genetic polymorphisms (genes investigated, genes involved, name and number of Single Nucleotide Polymorphisms (SNPs), main results).
Two independent reviewers (ZZ and ES) assessed whether the articles met the inclusion criteria. Disagreements were resolved through co-author team discussion. Each reviewer also assessed quality of the reporting of the studies and the risk of bias using a scoring system modified from a previously published study (Leusink et al., 2016) based on STREGA recommendations [see Supplementary Table 3; (Little et al., 2009)]. The scoring system resulted in an overall quality score of 0–10; studies with greater than or equal to half of the maximum points were regarded as of sufficient quality.
A meta-analysis could not be performed because of substantial differences in outcome definitions where some studies reported categorical outcome variables (e.g., CTCAE and the RIFLE classification [Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease]) while others reported continuous outcome variables (e.g., differences in serum creatinine [SCr], cystatin C, and estimated glomerular filtration rate [eGFR]). Further, we identified heterogeneity in statistical methods and in the reporting of effect size (few studies reported odds ratios while most reported only p-values), or in exposure categorization (i.e., dominant, co-dominant, or additive genetic inheritance models were assumed in different studies). Many articles lacked key data required for meta-analysis, such as the number of subjects experiencing nephrotoxicity per genotype category. Therefore, we report descriptively the results of SNPs that had been found to be associated with nephrotoxicity when they had been assessed in at least two independent study populations.
The article selection process is shown in Figure 1. The initial search delivered 359 articles; after removal of duplicates, 292 abstracts were primarily screened of which 105 full-text articles remained. After reading the full-text, 77 publications were excluded: three studies did not investigate cisplatin-based chemotherapy regimens, 72 studies did not evaluate relationships with nephrotoxicity, and two studies were confounded by concurrent radiation treatment. In the end, 28 studies were analyzed.
Figure 1. Flow chart of the selection of articles. This flow diagram is created according to the PRISMA recommendation (Moher et al., 2009).
The study characteristics of the 28 articles included, all were candidate gene studies published between 2008 and 2017, are shown in Table 1. Most were cohort studies (Wang et al., 2008; Filipski et al., 2009; Goekkurt et al., 2009; Chen et al., 2010; Khrunin et al., 2010a, 2012, 2014; KimCurran et al., 2011; Tzvetkov et al., 2011; Erculj et al., 2012; Iwata et al., 2012; Windsor et al., 2012; Xu et al., 2012, 2013; Zhang and Zhou, 2012; Zhang et al., 2012; Hinai et al., 2013; Khokhrin et al., 2013; Lamba et al., 2014; Yuan et al., 2015; Hattinger et al., 2016; Powrozek et al., 2016; Chang et al., 2017) and none were genome wide association studies (GWAS). Key details of subject characteristics [e.g., ethnicity and inclusion criteria (Sprowl et al., 2012)], type of chemotherapy regimens (Erculj et al., 2012; Sprowl et al., 2012; Powrozek et al., 2016), and nephrotoxicity criteria (Goekkurt et al., 2009; Kim et al., 2012; Khrunin et al., 2014) were not reported in some studies.
Of 3,799 adult subjects across these 28 studies, 1,443 patients (n = 13 studies) were predominantly of European Caucasians and 1,948 (n = 12 studies) were performed in East Asian populations. However, most studies did not explain how ancestry was determined. Individual study sizes ranged from 47 to 365 patients. Only six studies included more than 200 patients, while 12 studies had fewer than 100 subjects.
Ten studies involved lung cancer patients; five involved ovarian cancer; one study each evaluated gastric cancer, osteosarcoma, esophageal cancer, testicular cancer, and mesothelioma patients; six studies included various cancer types or did not mention the cancer type.
Chemotherapy Regimens Used
Different cancer sites used diverse drug combinations with cisplatin, and most studies evaluated more than one type of cisplatin combination therapy. Combinations with other drugs (Moon et al., 2011) and the dosage of cisplatin (Bennis et al., 2014) can influence the incidence of nephrotoxicity. Cisplatin + gemcitabine was the most commonly reported treatment regimen (n = 11 studies), followed by cisplatin + taxane (either cisplatin + docetaxel or cisplatin + paclitaxel, n = 10), cisplatin + etoposide (n = 7), cisplatin + cyclophosphamide (n = 5) and cisplatin + vinorelbine (n = 5). Cisplatin dosage also varied widely among studies: the lowest dose mentioned was 20 mg/m2 and the highest was 100 mg/m2 under a three-weekly schedule.
The National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) (Institute, 2016) criteria was the most commonly used classification of drug-induced nephrotoxicity (n = 15). Serum creatinine was used for classifying the severity of nephrotoxicity. The NCI-CTCAE 4.03 grading of acute kidney injury were as follows (Institute, 2016): Grade 1, a creatinine level increase of >0.3 mg/dL or a creatinine level that was 1.5–2.0 times above baseline; Grade 2, a creatinine level that was 2–3 times above baseline; Grade 3, either a creatinine that was >3 times above baseline or an absolute creatinine level of over 4.0 mg/dL or any rise that required hospitalization; Grade 4, life-threatening consequences or dialysis indicated. However, we found marked variability in the standard grading to determine nephrotoxicity. Eight studies defined nephrotoxicity as ≥grade 1, while three studies described nephrotoxicity as ≥grade 2, two studies provided no information regarding the standard, and other studies used changes in creatinine serum (n = 4), WHO criteria (n = 3), changes in creatinine clearance (n = 2) or changes in a novel urinary biomarker (n = 1). Three studies did not describe the nephrotoxicity criteria at all.
Quality Assessment and Quality of Reporting
Quality assessment was performed by two reviewers (ZZ and ES) using recommendations for reporting genetic association studies [(Little et al., 2009); Supplementary Table 4). Only 16 studies (42.8%) provided sufficient information according to the STrengthening the REporting of Genetic Association Studies (STREGA) recommendations. One of the items in the predetermined reporting criteria (multiple testing correction) was not reported by most studies because unlike GWAS, the majority of the studies were not investigating multiple genetic markers at once. Therefore, a large number of studies (n = 22; 79%) received a lower quality score. Note that if certain reporting requirements are of low relevance to the circumstances of the individual article, lower quality reporting scores do not necessarily reflect the research quality. As many as 24 studies (92%) did not report the power and sample size calculation, of which 12 studies (43%) showed no statistically significant associations. Nevertheless, seven of eight studies that showed a statistically significant association for ERCC1, ERCC2 and SLC22A2 also did not report power or sample calculations. Nine of 14 studies that showed no statistically significant association failed to report whether there were issues concerning genotyping quality, for example, by reporting the percentage of successful genotyping attempts or a cross validation with a different genotyping technique. For nine studies (32%), there were concerns about the quality of the study design and analysis. For example, the authors did not calculate and interpret the statistical interaction adequately. Within their Results sections, 15 and 10 studies did not report participants' characteristics and outcomes stratified by genotype, respectively. As many as 13 studies did not mention limitations of the study and sources of potential bias. In 19 studies (67.9%), the clinical information was of sufficient quality as the authors mentioned the specific cisplatin-based chemotherapy regimens and the dosage per cycle and the number of cycles, and there was an adequate methodologic description including participant selection, baseline characteristics, inclusion criteria, nephrotoxicity criteria (including objective lab parameters).
Genes Studied in Cisplatin-Induced Nephrotoxicity
Candidate genes of all 28 studies were chosen based on platinum pharmacokinetic or pharmacodynamic pathways. As many as 135 genes involved in DNA repair, drug transport, tumor suppression, regulation of intracellular process, or detoxification were investigated. The number of variants assessed per study ranged from 1 to 228 SNPs. From those 135 genes, 14 genes were associated with cisplatin-induced nephrotoxicity in at least one study: ERCC1 and ERCC2 (XPD), SLC22A2 (OCT2), SLC31A1 (CTR1), SLC47A1 (multidrug and toxin extrusion protein 1; MATE1), ABCC2 (multidrug resistance protein 2; MRP2), Kelch-like ECH-associated protein 1 (KEAP1), nuclear factor erythroid derived 2 like 2 (NFE2L2), GSTP1 (Glutathione S-Transferase Pi 1), GSTT1, methylene tetrahydrofolate reductase (MTHFR), epoxide hydrolase 1 (EPHX1), eukaryotic translation initiation factor 3 subunit A (eIF3a) and MMS19L. However, only SNPs from ERCC1, ERCC2 (XPD), and SLC22A2 (OCT2), consistently showed a positive association in at least two studies (Table 2).
Genetic Polymorphisms in ERCC1
Polymorphisms in the nucleotide excision repair genes ERCC1 and ERCC2 (XPD) have been linked to alterations of the DNA repair process and capacity (Giachino et al., 2007; Friboulet et al., 2013; Xiong et al., 2017); this is postulated to affect nephron repair after injury by platinum agent exposure. Furthermore, ERCC1 may affect target cell sensitivity to platinum-based therapy (Li et al., 2012, 2014; Bogush et al., 2015; Han et al., 2016) and patient response (Ryu et al., 2004; Cheng et al., 2012; Lv et al., 2014; Kaewbubpa et al., 2016; Li et al., 2016). Carriers of the wild-type C/C genotype of ERCC1 C118T (CC) (rs11615) had a higher chance of responding to platinum-based chemotherapy than patients carrying variant alleles (Cheng et al., 2012; Lv et al., 2014).
SNPs of ERCC1 (synonymous rs11615 and rs3212986 located at the 3′ UTR) were the most studied polymorphisms for cisplatin-induced nephrotoxicity. Associations between this gene and cisplatin nephrotoxicity were reported in two studies by (Khrunin et al., 2010b) and (Tzvetkov et al., 2011) in which the same SNPs (rs11615 and rs3212986) were investigated. (Khrunin et al., 2010b) observed that an increased risk for renal dysfunction was observed among epithelial ovarian cancer patients carrying the heterozygous genotype (TC) of rs11615 (46.7%) with an OR = 2.51 (95% CI 1.09–5.57; P = 0.037) and for carriers of the rs3212986 CA genotype (52.8%) with an OR = 3.29 (95% CI 1.40–7.73; P = 0.009), when compared with the patients carrying the homozygous variant genotype. (Tzvetkov et al., 2011) confirmed these results reporting that both SNP variants were statistically significantly associated with a fall in eGFR in various late-stage cancer patients (P < 0.05). However, the majority of the subjects (n = 47, 58.0%) had been previously treated with cisplatin. This may have affected the eGFR baseline which ranged from 40 to 167 ml/min/1.73 m2 and acted as a potential source of bias. Khrunin et al. (Khrunin et al., 2010b) defined nephrotoxicity as ≥1 grade of nephrotoxicity of NCI-CTCAE classification, while Tzvetkov et al. used relative change in the eGFR.
In contrast to the aforementioned results, 11 other studies, mostly underpowered, reported no statistically significant association between the ERCC1 polymorphisms and cisplatin nephrotoxicity (Goekkurt et al., 2009; Chen et al., 2010; KimCurran et al., 2011; Erculj et al., 2012; Khrunin et al., 2012, 2014; Windsor et al., 2012; Khokhrin et al., 2013; Liu et al., 2014; Hattinger et al., 2016; Powrozek et al., 2016). Thus, further studies to disclose molecular mechanisms of ERCC1-mediated cisplatin nephrotoxicity are needed as a scientific basis for a future clinical study.
Genetic Polymorphisms in ERCC2 (XPD)
Significant associations between variants in ERCC2 and cisplatin-induced nephrotoxicity were reported in four studies (Goekkurt et al., 2009; Kim et al., 2012; Windsor et al., 2012; Powrozek et al., 2016). However, there was high heterogeneity in study characteristics. Two studies (Windsor et al., 2012; Powrozek et al., 2016) were retrospective cohort studies while one was a prospective cohort (Goekkurt et al., 2009) and one was a case-control study (Kim et al., 2012). Three studies focused on individuals of European ancestry (Goekkurt et al., 2009; Windsor et al., 2012; Powrozek et al., 2016) while one study focused on East Asian patients (Kim et al., 2012). Two studies clearly defined nephrotoxicity based on NCI-CTCAE criteria, but there were differences in the nephroxicity threshold [≥grade 2 vs. ≥grade 1; (Windsor et al., 2012; Powrozek et al., 2016)] while two studies did not mention their definitions (Goekkurt et al., 2009; Kim et al., 2012). Of the six SNPs that showed statistically significant associations, only rs13181 survived replication.
Powrozek et al. showed that the A allele of 2251A > C (rs13181; p.Lys751Gln), a missense variant which potentially changes XPD protein expression and modulates nucleotide excision repair (Benhamou and Sarasin, 2002), was associated with a 14 and 4-fold greater cisplatin nephrotoxicity after the second and fourth chemotherapy cycle, respectively, through an allelic (not genotype) association analysis (Powrozek et al., 2016). Another study (Goekkurt et al., 2009) found that ~22% of 133 patients carrying the variant genotype of the ERCC2 rs13181 and ERCC2 rs1799793 suffered from grade 2–4 nephrotoxicity, which was significantly higher than in those carrying other genotypes; the OR for nephrotoxicity was 2.27 for the ERCC2 Asn312/751Gln (rs179979/rs13181, both are missense mutations) haplotype [P = 0.005; (Goekkurt et al., 2009)]. In contrast, Windsor et al. (Windsor et al., 2012) found that the AA genotype of ERCC2 rs13181 had a marginally lower nephrotoxicity risk after the second chemotherapy cycle (OR = 0.23, p = 0.044). Patients carrying AA genotype also experienced lower drops in eGFR than the AC/CC genotype (4 vs. 23 mL/min/1.73 m2, P = 0.021). Five studies displayed contradictory results when compared with the previously mentioned articles (Khrunin et al., 2010b, 2012, 2014; Erculj et al., 2012; Hattinger et al., 2016). Since ERCC2's role in cisplatin nephrotoxicity has not yet been fully understood, studies confirming the role of XPD proteins could help to uncover the molecular mechanisms underlying cisplatin nephrotoxicity. By manipulating ERCC2 gene expressions in suitable renal cell models, the role of XPD proteins in cisplatin nephrotoxicity could potentially be confirmed.
Genetic Polymorphism in SLC22A2 (OCT2)
Genes that encode for drug transport proteins, such as SLC22A2 (encoding the OCT2 protein) efficiently mediate the cellular uptake leading to high cisplatin accumulation particularly in renal proximal tubule in cells (Miller et al., 2010; Ciarimboli, 2012; Wensing and Ciarimboli, 2013). This condition accelerates the cytotoxic potential of the drug, including nuclear and mitochondrial DNA damage and production of reactive oxygen species (ROS), involved in pathways of apoptosis and necrosis (Miller et al., 2010). A nonsynonymous, missense mutation in SLC22A2 rs316019 (p.270Ala > Ser; G > T) was studied in seven studies in which four studies concluded that the variant genotype was protective against cisplatin nephrotoxicity.
Filipski et al. (Filipski et al., 2009) and Iwata et al. (Iwata et al., 2012) reported that patients carrying the wild-type genotype of rs316019 (GG) were more susceptible to cisplatin-induced nephrotoxicity compared to the other genotype, as defined by a statistically significantly increased serum creatinine (P < 0.05). Iwata et al. reported that wild-type GG had higher increase of serum creatinine than patients carrying the variant GT [1.11 ± 0.37 vs. 0.92 ± 0.15 mg/dL; P = 0.04; (Iwata et al., 2012)]. Zhang et al. (Zhang and Zhou, 2012) reported similar results in which the patients carrying the wildtype GG had higher levels of cystatin C than patients carrying the variant genotypes of GT and TT (0.043 ± 0.107 vs. −0.013 ± 0.120 mmol/L; P = 0.009). Each of those prospective cohort studies focused on malignant solid cancers in either European Caucasians or East Asians populations. The newest study by Chang et al. (Chang et al., 2017) in American Caucasians patients showed that patients carrying the GG genotype of rs316019 exhibited higher urinary fold changes in kidney injury molecule-1 (KIM-1) at day 3 after cisplatin administration (1.77 × 10171; P < 0.05) compared to the carriers of the other genotype. Higher reduction in eGFR and increase of blood urea nitrogen (BUN) in rs316019 wild-type GG genotype was also observed in two studies, although this was not statistically significant (Tzvetkov et al., 2011; Hinai et al., 2013). In contrast to these four studies, the remaining three studies (Khrunin et al., 2010a; Tzvetkov et al., 2011; Hinai et al., 2013) did not find any associations, but were generally underpowered, involved multiple types of cancer, and/or included both early and late stages in European and East Asian predominant populations, which may have contributed to the differences in results.
Summary of Main Results
To our knowledge, this is the first systematic review conducted to evaluate genetic markers associated with cisplatin nephrotoxicity. We report that eight germline polymorphisms had significant associations with cisplatin nephrotoxicity, of which variants in the genes ERCC1, ERCC2 (DNA repair) and SLC22A2 (drug transport) had consistent results across at least two independent populations.
Polymorphic variations of genes associated with the uptake of cisplatin from the renal proximal tubular cells, such as SLC31A1 (CTR1), SLC31A, SLC22A1-3 (OCT transport proteins), ATP7A and ATP7B (Copper-Transporting ATPases 1 and 2), and those that regulate the urinary cisplatin efflux from these cells, such as SLC47A1 (MATE1), ABCB1 (MDR1); ABCG2 (BCRP); ABCC1-2 (MRP1-2) have been evaluated (Aleksunes et al., 2008; Harrach and Ciarimboli, 2015) but only SLCC2A2 (SNP rs316019) was associated with cisplatin toxicity. By applying a dominant genetic model, three studies suggested that genotypes GT/TT of SLC22A2 rs316019 reported significant changes in kidney function biomarker that were considered clinically relevant. Studies from Japan and China reported up to 38% of changes in SCr [Mean difference: −0.19 mg/dL; (Iwata et al., 2012)] and up to 41% of changes in cystatin C [Mean difference: 0.056 mmol/L; (Zhang and Zhou, 2012)] compared to normal values [SCr: 0.6–1.2 mg/dl for male, 0.5–1.1 mg/dl for female; cystatin C: 0.068–0.118 mmol/L regardless gender; (Hosten, 1990; Finney et al., 2000)]. As SLC22A2 encodes the organic cation transporter 2 (OCT2), the association between rs316019 and SCr and eGFR might be due to an effect on tubular creatinine secretion; however, no clear evidence was found for a relationship between the SNP and cystatin C (Reznichenko et al., 2013). In addition, an elevation in KIM-1 (1.77 × 10171 fold) also indicates possible clinical relevance of this SNP (Chang et al., 2017). Further research measuring the eGFR changes and classifying the subjects into widely accepted CTCAE category would provide more insight into the importance of this SNP.
Rs316019 (c.808G > T; p.270Ala > Ser), the only common coding polymorphism within SLCC2A2 with an allele frequency ranging from 9 to 16%, is reported to cause changes in transporter function (Zolk, 2012). A report by Filipski et al. suggested that T allele in rs316019 is associated with decreased expression of SLC22A2 in a panel of human cell lines (Filipski et al., 2009). However, polymorphic variants of genes that regulate such transporters (e.g., OCT2, MATE1) in the cell still require further study. This will provide insight into the potential contribution of suspected transporter genes polymorphisms in cisplatin-induced nephrotoxicity, ototoxicity and neurotoxicity.
In cisplatin-induced nephrotoxicity, alteration of DNA repair mechanisms might play a role particularly in renal cells. Nucleotide excision repair genes are involved in the elimination of lesions that lead to distortion of the DNA helix structure (Bowden, 2014) and have been implicated in cisplatin outcome (ERCC1), sensitivity and resistance [ERCC2; (Bowden, 2014)]. Variations in ERCC may affect the repair function through alterations of protein or mRNA expression levels (Xiong et al., 2017) and Ercc1 mutant mice are deficient in several DNA repair processes that cause accelerated aging, particularly in non- or slowly proliferating organs (Niedernhofer et al., 2006). ERCC1 rs11615 is a synonymous variant while rs3212986 is located at the 3′ UTR (non-coding region); hence both SNPs are unlikely to produce amino acid changes that affect the DNA repair mechanism. However, the tissue expression quantitative trait loci (eQTL) analysis from GTEx reported a significant association between rs11615, rs3212986, and gene expression in various tissues (Group, 2017). Unfortunately, no association has been found between these SNPs and ERCC1 expression in kidney cortex tissue. In contrast, ERCC2 rs13181 (c.2251A > C), a missense non-synonymous variant resulting in amino acid changes from lysine to glycine (p.751Lys > Gln) is more likely to alter the DNA repair capacity (Duell et al., 2000; Lunn et al., 2000). However, the gene involvement in cisplatin-induced nephrotoxicity pathway have not been extensively studied (Zhu et al., 2015). Small study sizes, different ethnicities, varied and mixed cancer types, different combinations of chemotherapy, and different outcome definitions plague most of these analyses. Therefore, a large study with renal function as the primary outcome and with a clinically relevant nephrotoxicity threshold (e.g., ≥grade 2 CTCAE classification) should be conducted, particularly one that will consider a genetic risk score across multiple germline genes, possibly through a comprehensive GWAS or whole exome or whole genome sequencing approach.
Quality and Inconsistency Among Studies
Most studies did not report study power, provide a sample size calculation or report genotyping quality control tests, raising the possibility of underpowered false negative results [type II error; (Krzywinski and Altman, 2013)] and contributing to inconsistent results (Biau et al., 2008). Other reasons for conflicting results related to series of heterogeneous confounding variables typical in the setting of observational studies of toxicity: (1) differences in definition and grading of nephrotoxicity, (2) differences in baseline patient characteristics that could act as confounders of kidney function, (3) differences in chemotherapy regimens and use of other supportive drugs that could independently or additively predispose to nephrotoxicity (e.g., diuretics), (4) differences in cumulative or density of cisplatin dose and exposure time, (5) differences in the amount and the schedule of hydration across studies, and (6) possibility of gene-gene interactions that affect the cisplatin nephrotoxicity pathway. An example of these inconsistencies are the seven studies that evaluated the SLC22A2 gene. These studies varied in sample sizes between 53 and 206 patients, used five different nephrotoxicity standards, involved patients across various types of cancer and applied a mix of various different chemotherapy regimens. Moreover, two studies were conducted in women only. Despite these quality reporting issues, we were still able to identify four positively replicated SNPs across three genes. ERCC1, ERCC2, and SLC22A2 warrant further investigation.
Research and Clinical Implications
Studies that scan the entire genome, such as GWAS, are needed urgently (Zhu and Zhao, 2007), and can lead to the identification of novel genetic variants associated with nephrotoxicity. But these hypothesis-free approaches do require large sample sizes or rigorously phenotyped populations. The first observational study through genome-wide association and whole-genome sequencing studies to investigate drug-induced kidney disease—the DIRECT study is currently ongoing but the results are still pending (Awdishu et al., 2016). Because of patient heterogeneity, any genetic associations must take clinico-epidemiologic and demographic variations into account [e.g., performance status, regular use of NSAIDs, hypoalbuminemia, cardiac disease; (Kidera et al., 2014; Liu et al., 2014; Bhat et al., 2015; Miyoshi et al., 2016; Sato et al., 2016)], through proper documentation, prospective data collection, and appropriate adjustments during the statistical genetic analyses. Alternatively, population pharmacokinetic and/or pharmacodynamic modeling can be used as the basis of additional pharmacogenetic evaluations.
Despite more abundant reporting on ERCC1 and ERCC2 involvement in cisplatin nephrotoxicity, the SLC22A2 gene appeared to have the most consistent evidence of association with nephrotoxicity (same genetic models and across three different biomarkers (serum creatinine, cystatin C, KIM-1), though none of the studies reported eGFR and a magnitude of effect (i.e., odds ratio). Some studies reported the variants of ERCC1 and ERCC2 as risk factors while others reported the same variants as protective factors. In addition, SNP ERCC1 rs11615 and rs3212986 were not associated with changes in protein and mRNA expression (Woelfelschneider et al., 2008; Gao et al., 2011; Zhuo et al., 2018), and the studies on ERCC1 and ERCC2 polymorphisms primarily investigated efficacy as the main outcome, with nephrotoxicity as a secondary endpoint. In contrast, polymorphisms in SLC22A2–known to be highly expressed in kidney, have been consistently reported as protective factors against nephrotoxicity. Overall, SLC22A2 is the most promising candidate gene in predicting cisplatin nephrotoxicity with regard to having a biological explanation related to molecular mechanisms on cisplatin nephrotoxicity, where its encoded protein, OCT2, is directly involved in renal cisplatin uptake (Ciarimboli et al., 2005; Filipski et al., 2009; Yonezawa and Inui, 2011; Yonezawa, 2012). If validated further, SLC22A2 genetic testing may one day be implemented in the clinical setting, especially variant genotypes of SLC22A2 rs316019 provide protective factors toward cisplatin nephrotoxicity which may allow higher cisplatin doses to be administered. On the other hand, administration of an OCT2 inhibitor might minimize nephrotoxicity risk (Sprowl et al., 2013; Panesso et al., 2014; Ikemura et al., 2017) but with comparable hematotoxicity (Ikemura et al., 2017) in patients carrying the highest risk genotypes.
In patients at highest risk of nephrotoxicity, a number of potential other therapeutic options are available: magnesium supplementation (Crona et al., 2017) may reduce cisplatin accumulation by regulating the expression of the renal transporters rOCT2 and rMATE1 (Saito et al., 2017); switching to carboplatin may reduce the nephrotoxic potential, even though carboplatin may have lower response rates than cisplatin, along with a range of toxicities different from cisplatin (de Castria et al., 2013).
The systematic approach based on predetermined comprehensive PICOS criteria using established electronic databases is a strength of this review. In addition, we conducted the review according to the PRISMA guideline to minimize the selection bias (Supplementary Table 5). However, we were unable to perform a quantitative comparison and meta-analysis due to heterogeneity in study design, treatments, outcome measures, statistical measurement and the use of effect size.
To summarize, an increasing number of pharmacogenomics studies of cisplatin-induced nephrotoxicity has been published within the past decade. Review of these studies highlighted several genes that potentially affect the risk of cisplatin nephrotoxicity although limitations in study design, lack of reproducible results and lack of studies with sufficient quality remain a concern. In addition to transporter genes, DNA repair genes deserve further investigation to discern their putative role in cisplatin nephrotoxicity. The upcoming results of a genome-wide approach, such as used in the DIRECT study may have an advantage to address the limitations of the current studies, and take one step further toward the application of personalized and precision medicine in cancer patients treated with cisplatin.
ZZ, SV, and A-HM-vdZ research idea and study design. ZZ and SV search strategy and literature search. ZZ and SV data analysis/interpretation. ZZ and ES assessment of study quality and risk of bias. A-HM-vdZ, RM, and SV supervision or mentorship. ZZ made the first draft of manuscript. A-HM-vdZ, SV, RM, BC, GL, JV, and PB critically reviewed and revised the article. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This study was financially supported by Indonesia Endowment Fund for Education (LPDP) Ministry of Finance, the Republic of Indonesia as a part of ZZ's Ph.D. project (grant no. 20161022049506). The LPDP had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.01111/full#supplementary-material
Aleksunes, L. M., Augustine, L. M., Scheffer, G. L., Cherrington, N. J., and Manautou, J. E. (2008). Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 250, 82–88. doi: 10.1016/j.tox.2008.06.009
Awdishu, L., Nievergelt, C. M., Davenport, A., Murray, P. T., Macedo, E., Cerda, J., et al. (2016). Rationale and design of the genetic contribution to Drug Induced Renal Injury (DIRECT) study. Kidney Int. Rep. 1, 288–298. doi: 10.1016/j.ekir.2016.08.010
Barahmani, N., Carpentieri, S., Li, X.-N., Wang, T., Cao, Y., Howe, L., et al. (2009). Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 11, 292–300. doi: 10.1215/15228517-2008-089
Bennis, Y., Savry, A., Rocca, M., Gauthier-Villano, L., Pisano, P., and Pourroy, B. (2014). Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int. J. Clin. Pharm. 36, 420–429. doi: 10.1007/s11096-013-9912-7
Bhat, Z. Y., Cadnapaphornchai, P., Ginsburg, K., Sivagnanam, M., Chopra, S., Treadway, C. K., et al. (2015). Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS ONE 10:e0142225. doi: 10.1371/journal.pone.0142225
Biau, D. J., Kerneis, S., and Porcher, R. (2008). Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin. Orthop. Relat. Res. 466, 2282–2288. doi: 10.1007/s11999-008-0346-9
Bogush, T. A., Popova, A. S., Dudko, E. A., Bogush, E. A., Tyulyandina, A. S., Tyulyandin, S. A., et al. (2015). [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs]. Antibiot. Khimioter. 60, 42–50.
Chang, C., Hu, Y., Hogan, S. L., Mercke, N., Gomez, M., O'Bryant, C., et al. (2017). Pharmacogenomic variants may influence the urinary excretion of novel kidney injury biomarkers in patients receiving cisplatin. Int. J. Mol. Sci. 18:E1333. doi: 10.3390/ijms18071333
Chen, S., Huo, X., Lin, Y., Ban, H., Lin, Y., Li, W., et al. (2010). Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int. J. Hyg. Environ. Health 213, 140–145. doi: 10.1016/j.ijheh.2010.01.004
Cheng, J., Ha, M., Wang, Y., Sun, J., Chen, J., Wang, Y., et al. (2012). A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 138, 231–238. doi: 10.1007/s00432-011-1090-1
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstadt, H., Koepsell, H., Piechota, H. J., et al. (2005). Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167, 1477–1484. doi: 10.1016/S0002-9440(10)61234-5
Crona, D. J., Faso, A., Nishijima, T. F., McGraw, K. A., Galsky, M. D., and Milowsky, M. I. (2017). A Systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22, 609–619. doi: 10.1634/theoncologist.2016-0319
de Castria, T. B., da Silva, E. M., Gois, A. F., and Riera, R. (2013). Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 8:Cd009256. doi: 10.1002/14651858.CD009256
Duell, E. J., Wiencke, J. K., Cheng, T -J., Varkonyi, A., Zuo, Z. F., Ashok, T. D. S., et al. (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21, 965–971. doi: 10.1093/carcin/21.5.965
Erculj, N., Kovac, V., Hmeljak, J., and Dolzan, V. (2012). The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann. Oncol. 23, 961–967. doi: 10.1093/annonc/mdr324
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., and Sparreboom, A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396–402. doi: 10.1038/clpt.2009.139
Finney, H., Newman, D. J., and Price, C. P. (2000). Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann. Clin. Biochem. 37(Pt 1), 49–59. doi: 10.1258/0004563001901524
Friboulet, L., Olaussen, K. A., Pignon, J. P., Shepherd, F. A., Tsao, M. S., Graziano, S., et al. (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 368, 1101–1110. doi: 10.1056/NEJMoa1214271
Gao, R., Reece, K., Sissung, T., Reed, E., Price, D. K., and Figg, W. D. (2011). The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat. Res. 708, 21–27. doi: 10.1016/j.mrfmmm.2011.01.002
Giachino, D. F., Ghio, P., Regazzoni, S., Mandrile, G., Novello, S., Selvaggi, G., et al. (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin. Cancer Res. 13, 2876–2881. doi: 10.1158/1078-0432.CCR-06-2543
Gietema, J. A., Meinardi, M. T., Messerschmidt, J., Gelevert, T., Alt, F., Uges, D. R., et al. (2000). Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355, 1075–1076. doi: 10.1016/S0140-6736(00)02044-4
Goekkurt, E., Al-Batran, S. E., Hartmann, J. T., Mogck, U., Schuch, G., Kramer, M., et al. (2009). Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 27, 2863–2873. doi: 10.1200/JCO.2008.19.1718
Group, G. C. A. W. (2017). GTEx Portal. The Broad Institute of MIT and Harvard. Available online at: https://gtexportal.org/ (Accessed 2018).
Gullo, J. J., Litterst, C. L., Maguire, P. J., Sikic, B. I., Hoth, D. F., and Woolley, P. V. (1980). Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother. Pharmacol. 5, 21–26. doi: 10.1007/BF00578558
Han, Y., Liu, J., Sun, M., Zhang, Z., Liu, C., and Sun, Y. (2016). A Significant statistical advancement on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer: an updated meta-analysis. Dis. Markers 2016:7643981. doi: 10.1155/2016/7643981
Hattinger, C. M., Biason, P., Iacoboni, E., Gagno, S., Fanelli, M., Tavanti, E., et al. (2016). Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget 7, 61970–61987. doi: 10.18632/oncotarget.11486
Hinai, Y., Motoyama, S., Niioka, T., and Miura, M. (2013). Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. J. Clin. Pharm. Ther. 38, 498–503. doi: 10.1111/jcpt.12097
Hjelle, L. V., Gundersen, P. O., Oldenburg, J., Brydoy, M., Tandstad, T., Wilsgaard, T., et al. (2015). Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study. Anticancer Res. 35, 1619–1625.
Ikemura, K., Oshima, K., Enokiya, T., Okamoto, A., Oda, H., Mizuno, T., et al. (2017). Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. Cancer Chemother. Pharmacol. 79, 943–949. doi: 10.1007/s00280-017-3296-7
Institute, N. C. (2016). Common Terminology Criteria for Adverse Events (CTCAE). Available online at: https://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx (Accessed).
Iwata, K., Aizawa, K., Kamitsu, S., Jingami, S., Fukunaga, E., Yoshida, M., et al. (2012). Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin. Exp. Nephrol. 16, 843–851. doi: 10.1007/s10157-012-0638-y
Jimenez-Triana, C. A., Castelan-Martinez, O. D., Rivas-Ruiz, R., Jimenez-Mendez, R., Medina, A., Clark, P., et al. (2015). Cisplatin nephrotoxicity and longitudinal growth in children with solid tumors: a retrospective cohort study. Medicine (Baltimore) 94:e1413. doi: 10.1097/MD.0000000000001413
Kaewbubpa, W., Areepium, N., and Sriuranpong, V. (2016). Effect of the ERCC1 (C118T) polymorphism on treatment response in advanced non-small cell lung cancer patients undergoing platinum-based chemotherapy. Asian Pac. J. Cancer Prev. 17, 4917–4920. doi: 10.22034/APJCP.2016.17.11.4917
Khokhrin, D. V., Khrunin, A. V., Ivanova, F. G., Moisseev, A. A., Gorbunova, V. A., and Limborska, S. A. (2013). Pharmacogenomics of cisplatin-based chemotherapy in ovarian-cancer patients from Yakutia. Mol. Genet. Microbiol. Virol. 28, 137–140. doi: 10.3103/S0891416813040034
Khrunin, A., Ivanova, F., Moisseev, A., Khokhrin, D., Sleptsova, Y., Gorbunova, V., et al. (2012). Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 13, 171–178. doi: 10.2217/pgs.11.140
Khrunin, A. V., Khokhrin, D. V., Moisseev, A. A., Gorbunova, V. A., and Limborska, S. A. (2014). Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 15, 329–337. doi: 10.2217/pgs.13.237
Khrunin, A. V., Moiseev, A. A., Khokhrin, D. V., Gorbunova, V. A., and Limborska, S. A. (2010a). Polymorphisms of OCT2, GGT1, HO1, and DNASE1 genes and nephrotoxicity of cysplatin in ovarian cancer patients. Mol. Genet. Microbiol. Virol. 25, 163–166. doi: 10.3103/S089141681004004X
Khrunin, A. V., Moisseev, A., Gorbunova, V., and Limborska, S. (2010b). Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10, 54–61.
Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., et al. (2014). Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE 9:e101902. doi: 10.1371/journal.pone.0101902
Kim, S. H., Lee, G. W., Lee, M. J., Cho, Y. J., Jeong, Y. Y., Kim, H. C., et al. (2012). Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Lung Cancer 77, 578–584. doi: 10.1016/j.lungcan.2012.04.016
KimCurran, V., Zhou, C., Schmid-Bindert, G., Ren, S. X., Zhou, S., Zhang, L., et al. (2011). Lack of correlation between ERCC1 (C8092A) Single Nucleotide Polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv. Med. Sci. 56, 30–38. doi: 10.2478/v10039-011-0013-3
Lamba, J. K., Fridley, B. L., Ghosh, T. M., Yu, Q., Mehta, G., and Gupta, P. (2014). Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15, 1565–1574. doi: 10.2217/pgs.14.107
Leusink, M., Onland-Moret, N. C., de Bakker, P. I., de Boer, A., and Maitland-van der Zee, A. H. (2016). Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics 17, 163–180. doi: 10.2217/pgs.15.158
Li, F., Xie, X., Ren, X., and Zhang, J. (2016). A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother. Pharmacol. 77, 1183–1191. doi: 10.1007/s00280-016-3015-9
Li, Y., Hu, P., Cao, Y., Wang, G. Y., Wang, N., and Zhou, R. M. (2014). Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis. Biomarkers 19, 128–134. doi: 10.3109/1354750X.2014.882414
Little, J., Higgins, J. P., Ioannidis, J. P., Moher, D., Gagnon, F., von Elm, E., et al. (2009). Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J. Clin. Epidemiol. 62, 597.e594–608.e594. doi: 10.1016/j.jclinepi.2008.12.004
Liu, H. E., Bai, K. J., Hsieh, Y. C., Yu, M. C., Lee, C. N., Chang, J. H., et al. (2014). Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients. Biomed. Res. Int. 2014:937429. doi: 10.1155/2014/937429
Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K., et al. (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21, 551–555. doi: 10.1093/carcin/21.4.551
Lv, H., Han, T., Shi, X., Yao, Y., Yao, Y., Qiu, W., et al. (2014). Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med. Oncol. 31:86. doi: 10.1007/s12032-014-0086-5
Miyoshi, T., Misumi, N., Hiraike, M., Mihara, Y., Nishino, T., Tsuruta, M., et al. (2016). Risk factors associated with cisplatin-induced nephrotoxicity in patients with advanced lung cancer. Biol. Pharm. Bull. 39, 2009–2014. doi: 10.1248/bpb.b16-00473
Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6:e1000097. doi: 10.1371/journal.pmed.1000097
Moon, H. H., Seo, K. W., Yoon, K. Y., Shin, Y. M., Choi, K. H., and Lee, S. H. (2011). Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J. Gastroenterol. 17, 3510–3517. doi: 10.3748/wjg.v17.i30.3510
Niedernhofer, L. J., Garinis, G. A., Raams, A., Lalai, A. S., Robinson, A. R., Appeldoorn, E., et al. (2006). A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038–1043. doi: 10.1038/nature05456
Panesso, M. C., Shi, M., Cho, H. J., Paek, J., Ye, J., Moe, O. W., et al. (2014). Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int. 85, 855–870. doi: 10.1038/ki.2013.489
Percie du Sert, N., Rudd, J. A., Apfel, C. C., and Andrews, P. L. (2011). Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists. Cancer Chemother. Pharmacol. 67, 667–686. doi: 10.1007/s00280-010-1339-4
Powrozek, T., Mlak, R., Krawczyk, P., Homa, I., Ciesielka, M., Koziol, P., et al. (2016). The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients. Clin. Transl. Oncol. 18, 125–131. doi: 10.1007/s12094-015-1343-6
Reznichenko, A., Sinkeler, S. J., Snieder, H., van den Born, J., de Borst, M. H., Damman, J., et al. (2013). SLC22A2 is associated with tubular creatinine secretion and bias of estimated GFR in renal transplantation. Physiol. Genomics 45, 201–209. doi: 10.1152/physiolgenomics.00087.2012
Ryu, J. S., Hong, Y. C., Han, H. S., Lee, J. E., Kim, S., Park, Y. M., et al. (2004). Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44, 311–316. doi: 10.1016/j.lungcan.2003.11.019
Saito, Y., Okamoto, K., Kobayashi, M., Narumi, K., Yamada, T., and Iseki, K. (2017). Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters. Eur. J. Pharmacol. 811, 191–198. doi: 10.1016/j.ejphar.2017.05.034
Sato, K., Watanabe, S., Ohtsubo, A., Shoji, S., Ishikawa, D., Tanaka, T., et al. (2016). Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16:222. doi: 10.1186/s12885-016-2271-8
Schellens, J. H., Planting, A. S., Ma, J., Maliepaard, M., de Vos, A., de Boer Dennert, M., et al. (2001). Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 12, 667–675. doi: 10.1097/00001813-200109000-00004
Sprowl, J. A., Gregorc, V., Lazzari, C., Mathijssen, R. H., Loos, W. J., and Sparreboom, A. (2012). Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clin. Pharmacol. Ther. 91, 1022–1026. doi: 10.1038/clpt.2011.330
Sprowl, J. A., van Doorn, L., Hu, S., van Gerven, L., de Bruijn, P., Li, L., et al. (2013). Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin. Pharmacol. Ther. 94, 585–592. doi: 10.1038/clpt.2013.145
Tzvetkov, M. V., Behrens, G., O'Brien, V. P., Hohloch, K., Brockmoller, J., and Benhr, P. (2011). Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 12, 1417–1427. doi: 10.2217/pgs.11.93
van der Schoot, G. G. F., Westerink, N. L., Lubberts, S., Nuver, J., Zwart, N., Walenkamp, A. M. E., et al. (2016). Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients. Eur. J. Cancer. 59, 134–141. doi: 10.1016/j.ejca.2016.02.013
Wang, Z., Xu, B., Lin, D., Tan, W., Leaw, S., Hong, X., et al. (2008). XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62, 99–104. doi: 10.1016/j.lungcan.2008.02.019
Windsor, R. E., Strauss, S. J., Kallis, C., Wood, N. E., and Whelan, J. S. (2012). Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 118, 1856–1867. doi: 10.1002/cncr.26472
Woelfelschneider, A., Popanda, O., Lilla, C., Linseisen, J., Mayer, C., Celebi, O., et al. (2008). A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 29, 1758–1764. doi: 10.1093/carcin/bgn067
Xiong, Y., Huang, B. Y., and Yin, J. Y. (2017). Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med. Oncol. 34:48. doi: 10.1007/s12032-017-0905-6
Xu, X., Han, L., Duan, L., Zhao, Y., Yang, H., Zhou, B., et al. (2013). Association between eIF3alpha polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients. Br. J. Clin. Pharmacol. 75, 516–523. doi: 10.1111/j.1365-2125.2012.04379.x
Xu, X., Ren, H., Zhou, B., Zhao, Y., Yuan, R., Ma, R., et al. (2012). Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 77, 438–442. doi: 10.1016/j.lungcan.2012.03.023
Yonezawa, A., and Inui, K -I. (2011). Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol. 81, 563–568. doi: 10.1016/j.bcp.2010.11.016
Yuan, Z. J., Zhou, W. W., Liu, W., Wu, B. P., Zhao, J., Wu, W., et al. (2015). Association of GSTP1 and RRM1 polymorphisms with the response and toxicity of gemcitabine-cisplatin combination chemotherapy in chinese patients with non-small cell lung cancer. Asian Pac. J. Cancer Prev. 16, 4347–4351. doi: 10.7314/APJCP.2015.16.10.4347
Zhang, J., and Zhou, W. (2012). Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol. 50, 2289–2293. doi: 10.1016/j.fct.2012.03.077
Zhang, L., Gao, G., Li, X., Ren, S., Li, A., Xu, J., et al. (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS ONE 7:e48350. doi: 10.1371/journal.pone.0048350
Zhuo, Z. J., Liu, W., Zhang, J., Zhu, J., Zhang, R., Tang, J., et al. (2018). Functional polymorphisms at ERCC1/XPF genes confer neuroblastoma risk in chinese children. EBioMedicine 30, 113–119. doi: 10.1016/j.ebiom.2018.03.003
Keywords: cisplatin, nephrotoxicity, genetic variations, pharmacogenomics, precision medicine, kidney, toxicity
Citation: Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, Baas P, Masereeuw R and Maitland-van der Zee A-H (2018) Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. Front. Pharmacol. 9:1111. doi: 10.3389/fphar.2018.01111
Received: 06 June 2018; Accepted: 10 September 2018;
Published: 27 September 2018.
Edited by:Vita Dolzan, University of Ljubljana, Slovenia
Reviewed by:Julio Benitez, Universidad de Extremadura, Spain
Dylan Glubb, QIMR Berghofer Medical Research Institute, Australia
Copyright © 2018 Zazuli, Vijverberg, Slob, Liu, Carleton, Veltman, Baas, Masereeuw and Maitland-van der Zee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anke-Hilse Maitland-van der Zee, firstname.lastname@example.org